Company profile
Radnostix, Inc.
OTC: INIS · Healthcare · Drug Manufacturers - Specialty & Generic
#599 of 1,418 Healthcare companies by revenue34th-percentile growth
EA Score
51DFH 54DQ 38GM 58SS 65
v0.1 · 65/100 weight · provisional
↑ listing tenure, growth stability · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$12.2M
Rev growth YoY (TTM)
-14.2%
Net income (FY)
-$908.0k
Employees
45
as of 2026-08-20
Market cap
$31.7M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.1M$13.1M2025
Net income-$908.0k-$908.0k2025
Operating income-$956.2k-$956.2k2025
Total assets$17.8M$17.8M2025
Liabilities$14.1M$14.1M2025
Equity$3.7M$3.7M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Cobalt Products100%
By geography
Not disclosed.
The read
What is Radnostix, Inc.’s revenue?
Radnostix, Inc. booked $13.1M in FY2025 revenue, contracting 6.0% year over year — slower than 66% of Healthcare companies we track, at a -6.9% net margin.
Peers · Healthcare
Novo Integrated Sciences, Inc.——Mednow Inc.——Tonix Pharmaceuticals Holding Corp.45DLeveljump Healthcare Corp.——Spero Therapeutics, Inc.68BLumos Diagnostics Holdings Ltd.45DKey facts
CEOShahe Bagerdjian
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersIdaho Falls, ID
ExchangeOTC: INIS
Employees45
IPO date1997-08-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.